Failing immunity has been acknowledged for its contribution to cancer development and progression. Recent clinical findings have provided payoffs for significant preclinical evaluation and refinement over the last 20 years, but many questions remain to be answered. In this issue of the
Cristina Ghirelli, Thorsten Hagemann
Marabelle et al. showed how local immunotherapy in mice helps the eradication of tumors at distant sites, even in an immune-privileged site such as the brain.